PMC:7195088 / 27914-28276 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T139","span":{"begin":12,"end":20},"obj":"Disease"},{"id":"T140","span":{"begin":146,"end":154},"obj":"Disease"},{"id":"T141","span":{"begin":270,"end":278},"obj":"Disease"},{"id":"T142","span":{"begin":281,"end":290},"obj":"Disease"}],"attributes":[{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"evalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T151","span":{"begin":240,"end":241},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"evalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T369","span":{"begin":81,"end":100},"obj":"Chemical"},{"id":"T370","span":{"begin":81,"end":90},"obj":"Chemical"},{"id":"T371","span":{"begin":91,"end":100},"obj":"Chemical"},{"id":"T372","span":{"begin":331,"end":349},"obj":"Chemical"}],"attributes":[{"id":"A369","pred":"chebi_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A370","pred":"chebi_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A371","pred":"chebi_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A372","pred":"chebi_id","subj":"T372","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"evalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo "}

{"project":"LitCovid-sentences","denotations":[{"id":"T210","span":{"begin":43,"end":155},"obj":"Sentence"},{"id":"T211","span":{"begin":156,"end":207},"obj":"Sentence"},{"id":"T212","span":{"begin":208,"end":225},"obj":"Sentence"},{"id":"T213","span":{"begin":226,"end":314},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"evalence of COVID-19 (follow-up 12 weeks).\n• Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).\n• Comparison of hydroxychloroquine vs. placebo "}